Fig. 2
From: Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases
KDS12025 enhances Hb pseudoperoxidase activity. a Comparison of H2O2 decomposition by HRP and Hb after drug treatment (10 μM) for 30 min via the ROS-Glo assay. b Fold change (vehicle difference divided by drug difference) in H2O2 decomposition facilitated by HRP and Hb under drug conditions. c Experimental timeline investigating Hb intrinsic peroxidase activity and enhancement by drug preincubation. d Hb peroxidase activity and dose-dependent effects of drugs (D, DMSO; H, HTPEB; K, KDS12025) at various Hb concentrations. e Dose‒response curve showing the EC50 and EC20 values for Hb H2O2 decomposition activity. f, g Bubble generation observed from CAT, HRP, and Hb in reaction with H2O2 under a microscope and quantified per 1 × 1 mm2 area. h Schematic and quantification of bubble liberation volumes measured in the cylinders. i Schematic of arterial blood collection by direct cardiac puncture. P50 values (mmHg), calculated from pO2 and SO2 using the i-STAT analyzer, between vehicle- and KDS12025-treated mice (0.1, 1, or 10 mg/kg, i.p., 24 h). j Arterial Hb concentration (g/dL) across groups. k Timeline of the PhenoMaster experiments investigating the metabolic effects of KDS12025 at different concentrations (0.1, 1, and 10 mg/kg/day). Measurements of oxygen consumption (l), carbon dioxide production (m), and the respiratory exchange ratio (RER; L) (n) during night (dark) and day (white) cycles, with a summary graph provided. The EC20 and EC50 values were determined via GraphPad Prism software. The data are presented as the means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001; ns not significant. Additional statistics are provided in Supplementary Table 8
